ArtVentive Medical Group has frozen its Endoluminal Occlusion (EOS) device design for the peripheral category of indications in preparation for the company’s regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
The EOS is a catheter based self-expandable device, serving for permanent or temporary (reversible) occlusion of body lumens.
ArtVentive said the patented device will serve in many cases as a safe and reliable alternative to major surgery.
ArtVentive’s EOS device targets a substantive market demand in several major clinical areas, including women’s health, peripheral and neurological vascular disorders in addition to interventional cardiology procedures.